CLINICAL_TRIALS
trial_result
· 2016-06-09
Clinical Trial Update: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) [Phase 1]
Summary
Phase 1 study of intravenous MK-8226 in moderate-to-severe atopic dermatitis was terminated; results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Atopic Dermatitis | Phase 1 | Status: TERMINATED | Results posted: 2016-06-09